Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081940 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL15713879 | 0.81 | MEN1 (0.49) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL1528572 | 0.81 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL10964298 | 0.79 | MAP2K4 (0.47) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| Bromide SCHEMBL11863184 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| Hydrochloric Acid SCHEMBL11875073 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL30639623 | 0.78 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL8842823 | 0.76 | RAB9A (0.50) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL18770477 | 0.75 | HSP90AA1 (0.44) | ALDH1A1KDM4EHPGDGAAMAPK10 | |
| SCHEMBL28003108 | 0.75 | SMPD3 (0.46) | ALDH1A1KDM4EHPGDGAAMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102170787-A | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies | PROTEOTECH INC | 2011-08-31 | — | — | CN | claimed |
| US-11155969-B2 | Polystyrene-based structural materials | GAINES DANIEL P (US) | 2021-10-26 | — | — | US | disclosed |
| US-20180313041-A1 | Polystyrene-Based Structural Materials | GAINES DANIEL P (US) | 2018-11-01 | — | — | US | disclosed |
| WO-2018045387-A1 | POLYMER NANOPARTICLE THERMAL INSULATORS | NanoSD Inc. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180066131-A1 | POLYMER NANOPARTICLE THERMAL INSULATORS | NanoSD Inc. | 2018-03-08 | — | — | US | disclosed |
| CN-101720318-B | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SRL | 2014-03-12 | — | — | CN | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| WO-2013064919-A1 | QUINAZOLINE DERIVATIVES WITH HSP90 INHIBITORY ACTIVITY | DAC SRL (IT) | 2013-05-10 | — | — | WO | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| CN-101720318-A | Quinazoline-oxime derivatives as Hsp90 inhibitors | DAC SRL | 2010-06-02 | — | — | CN | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ALDH1A1 1998/4885KDM4E 2835/4885HPGD 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.